Blog
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
…
17th Dec 2025
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
…
17th Dec 2025
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
…
16th Jan 2025
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars
Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
…
16th Jan 2025
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy
What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
…
16th Jan 2025
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research
What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
…
15th Jan 2025
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation
What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
…
15th Jan 2025
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research
What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
…
15th Jan 2025
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research
Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
…
15th Jan 2025
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research
Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
…
15th Jan 2025
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research
Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili
…
15th Jan 2025
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy
Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
…
15th Jan 2025
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research
What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
…
14th Jan 2025
Enoblituzumab: Unveiling the Role of Anti-B7-H3 in Cancer Research
Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin
…
14th Jan 2025
Targeting IL-10R: Enhancing Immune Activation in Cancer
Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
…
12th Dec 2024
Pinatuzumab: Advancing Cancer Research and Therapeutics
Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
…
12th Dec 2024
Belantamab: A Game-Changer in Multiple Myeloma Therapy
Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
…
12th Dec 2024
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology
Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
…
12th Dec 2024
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy
Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
…
12th Dec 2024
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research
Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
…
10th Dec 2024
Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research
Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i
…
10th Dec 2024
Varlilumab: Unlocking CD27’s Potential in Cancer Research
What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
…
5th Dec 2024
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies
1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive c
…
5th Dec 2024
CB6 Biosimilar: Targeting SARS-CoV-2 with Cost-Effective Monoclonal Antibody Therapy
CB6, also known as Etesevimab, is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It neutralizes the virus by preventing it from bind
…
4th Dec 2024